secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioRestorative Therapies, Inc. (BRTX)
CIK:        0001505497
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001021771-24-000027
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease
--------------------------------------------------------------------------------

- Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.
- Pain and function scales (VAS, ODI, RMDQ, FRI) show positive trend vs baseline at both follow-up points.
- No notable safety signals observed in the ongoing study for chronic lumbar disc disease.
- Company will host webcasted conference call today Feb 5 at 8:30am ET to discuss data and clinical update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505497/000102177124000027/0001021771-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505497/000102177124000027/brt8k2524.htm
  HTML page:      https://secwatch.observer/filing/0001021771-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer